Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 17/20 | 0.53 |
| ▸ | TBXA2R | P21731 | 5/20 | 0.52 |
| ▸ | PTGDR | Q13258 | 5/20 | 0.52 |
| ▸ | CETP | P11597 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | PTGIR | P43119 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL139367 | 0.90 | PTGDR2 (0.50) | PTGDR2TBXA2RPTGDRCETPCYP3A4 | |
| SCHEMBL1641287 | 0.90 | PTGDR2 (0.44) | PTGDR2TBXA2RPTGDRCETPCYP3A4 | |
| SCHEMBL156552 | 0.90 | PTGDR2 (0.62) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL137125 | 0.88 | PDK2 (0.43) | PTGDR2TBXA2RPTGDRCETPCYP3A4 | |
| SCHEMBL1641289 | 0.87 | PDK2 (0.42) | PTGDR2TBXA2RPTGDRCETPCYP3A4 | |
| SCHEMBL1643183 | 0.84 | KDM4E (0.44) | PTGDR2TBXA2RPTGDR | |
| SCHEMBL148588 | 0.84 | PTGDR2 (0.54) | PTGDR2TBXA2RPTGDRCETPCYP3A4 | |
| SCHEMBL134607 | 0.84 | ABL1 (0.47) | PTGDR2 | |
| SCHEMBL148769 | 0.83 | PTGDR2 (0.61) | PTGDR2TBXA2RPTGDRCETPCYP3A4 | |
| SCHEMBL151784 | 0.82 | PTGDR2 (0.60) | PTGDR2TBXA2RPTGDRCETPCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9572785-B2 | DP2 antagonist and uses thereof | BRICKELL BIOTECH, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20160136119-A1 | DP2 ANTAGONIST AND USES THEREOF | BRICKELL BIOTECH, INC. | 2016-05-19 | — | — | US | disclosed |
| EP-2257524-B1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | BRICKELL BIOTECH INC (US) | 2016-01-06 | — | — | EP | disclosed |
| EP-2257524-B1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | BRICKELL BIOTECH INC (US) | 2016-01-06 | — | — | EP | disclosed |
| US-8815917-B2 | DP2 antagonist and uses thereof | PANMIRA PHARMACEUTICALS, LLC (US) | 2014-08-26 | — | — | US | disclosed |
| US-8524748-B2 | Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524748-B2 | Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-09-03 | — | — | US | disclosed |
| US-8497381-B2 | Antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-07-30 | — | — | US | disclosed |
| US-8497381-B2 | Antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-07-30 | — | — | US | disclosed |
| US-20130158036-A1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-06-20 | — | — | US | disclosed |
| EP-2245022-A2 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | Amira Pharmaceuticals, Inc. (US) | 2010-11-03 | — | — | EP | disclosed |
| EP-2245002-A1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | Amira Pharmaceuticals, Inc. (US) | 2010-11-03 | — | — | EP | disclosed |
| WO-2010042652-A2 | HETEROALKYL BIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | WO | disclosed |
| WO-2010042652-A2 | HETEROALKYL BIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | WO | disclosed |
| WO-2009108720-A2 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009108720-A2 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009099902-A1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009099902-A1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009099901-A1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090197959-A1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158036-A1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | PTGDR2 2/4885TBXA2R 12/4885PTGDR 1/4885 |
| US-20090197959-A1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGIR | PTGDR2 2/4885TBXA2R 6/4885PTGDR 1/4885 |
| US-20160136119-A1 | DP2 ANTAGONIST AND USES THEREOF | PTGER2, PTGES2, PTGDR2 | PTGDR2 3/4885TBXA2R 20/4885PTGDR 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.